ホーム › 非ホジキンリンパ腫 › マサチューセッツ州 › Boston
Boston、MAにおける非ホジキンリンパ腫の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、非ホジキンリンパ腫に関する26件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
被験者募集中第1/2相
- Research Site, Boston
- Research Site, Boston
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
被験者募集中第2相
- Boston Medical Center, Boston
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
被験者募集中第1相
- Tufts Medical Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
被験者募集中観察研究
- Dana Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
被験者募集中第1相健康なボランティア歓迎
- Brigham and Women's Hospital, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- Dana Farber Cancer Institute, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
被験者募集中観察研究
- Dana-Farber Cancer Institute, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
被験者募集中
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
被験者募集中第1相
- Massachusetts General Hospital, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
被験者募集中第2相
- Beth Israel Deaconess Medical Center, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
被験者募集中第2相健康なボランティア歓迎
- DFCI/BWH Brigham and Women's Hospital, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
被験者募集中第4相
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
被験者募集中第4相
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
他の都市における非ホジキンリンパ腫の試験
- New York City, NY31件の研究
- Houston, TX31件の研究
- Nashville, TN21件の研究
- Philadelphia, PA20件の研究
- Baldwin Park, CA19件の研究
- Washington, DC18件の研究
- Chicago, IL18件の研究
- Atlanta, GA18件の研究
- Milwaukee, WI18件の研究
- Columbus, OH18件の研究
- Dallas, TX17件の研究
- Seattle, WA16件の研究
Bostonにおける他の研究
- 乳がん112件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）85件の研究
- 転移性癌63件の研究
- 大腸癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。